comparemela.com

Latest Breaking News On - Nct03391466 - Page 1 : comparemela.com

FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.

Mehrdad mobasherFrank neumannClinical development at kiteClinical developmentLabel updates for zanubrutinibAlpine trialPatients with relapsed refractory chronic lymphocytic leukemiaAxicabtagene ciloleucelZuma 7 trialPatients with relapsed refractory largeb cell lymphoma

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Little rockUnited statesUniversity of arkansasAakash mukherjeeDepartment of internal medicineCollege of medicineWinthropp rockefeller cancer instituteWinthropp rockefeller cancer institute transplant centerCancer institute transplant centerCancer instituteMedical sciencesInternal medicineContributing kiteRelapsed refractoryb cell lymphomaPatients with relapsed refractory diffuse largeb cell lymphomaScholar 1 study

vimarsana © 2020. All Rights Reserved.